TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less.....

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: YxY who wrote (15781)	4/3/2000 10:59:00 PM
From: SnowShredder	Read Replies (1) of 59879

Hi YxY, Money is a good pt, as any company cannot survive w/o it, but think of it this way...if the technology is good the $$$ will find it...as long as the company can keep it's head a float that is. >gg< That is why I also try and look @ companies that will have some type of revenue soon with products in late stages...as well as their product having some type of significant advantage over what is currently available. Although on occassion if I think something is a slam dunk, I'm willing to wait. how NGEN technology compared to AFFX If I remember correctly (it's been a while since I looked, so you might want to double check) I think NGEN can give you faster results, but AFFX can scan more mutations on one chip. I think AFFX has a head start in distribution of its system distributing them through Amersham Pharmacia Biotech (I'm not sure who NGEN uses, I haven't recieved any info on their system). Best of Luck, Where'd He Go?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next